ADCC enhancement: A conundrum or a boon to mAb therapy?

Area of Science:

• Immunology
• Biotechnology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) are crucial for disease treatment, with therapeutic efficacy mediated by immune cells.
• Key mechanisms for mAb efficacy include antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
• Research efforts focus on enhancing ADCC and CDC to improve mAb therapeutic outcomes.

Purpose of the Study:

• To review and detail strategies aimed at enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) for improved monoclonal antibody (mAb) therapeutics.
• To provide an overview of technologies developed for ADCC enhancement.
• To present perspectives on the success and limitations of current ADCC enhancement strategies.

Main Methods:

• Review of scientific literature on strategies to enhance ADCC.
• Analysis of approaches that modify effector cells or the antibody itself.
• Examination of various ADCC enhancement technologies.

Main Results:

• Several strategies and technologies have been developed to enhance ADCC.
• These approaches involve altering components of the ADCC mechanism, such as effector cells or the antibody.
• The success of these technologies varies across different antibody therapeutics.

Conclusions:

• Enhancing ADCC is a key strategy for developing more efficacious mAb therapeutics.
• Modifications to effector cells and antibodies can significantly improve therapeutic responses.
• Further research and development are needed to optimize ADCC enhancement technologies for broader application.